JP2003149096A - Blood filter film and method therefor - Google Patents
Blood filter film and method thereforInfo
- Publication number
- JP2003149096A JP2003149096A JP2001342484A JP2001342484A JP2003149096A JP 2003149096 A JP2003149096 A JP 2003149096A JP 2001342484 A JP2001342484 A JP 2001342484A JP 2001342484 A JP2001342484 A JP 2001342484A JP 2003149096 A JP2003149096 A JP 2003149096A
- Authority
- JP
- Japan
- Prior art keywords
- membrane
- film
- blood
- whole blood
- honeycomb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 41
- 239000008280 blood Substances 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 16
- 239000012528 membrane Substances 0.000 claims description 41
- 239000011148 porous material Substances 0.000 claims description 33
- 238000001914 filtration Methods 0.000 claims description 17
- 229920001610 polycaprolactone Polymers 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 7
- 238000002615 hemofiltration Methods 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 abstract description 17
- 210000002381 plasma Anatomy 0.000 abstract description 12
- 210000002966 serum Anatomy 0.000 abstract description 8
- 210000000601 blood cell Anatomy 0.000 abstract description 6
- 239000006185 dispersion Substances 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 10
- 238000005266 casting Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000003799 water insoluble solvent Substances 0.000 description 2
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101001094026 Synechocystis sp. (strain PCC 6803 / Kazusa) Phasin PhaP Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000070 poly-3-hydroxybutyrate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、全血から血球を除
去するための濾過膜、およびその濾過膜を用いて全血か
ら赤血球あるいは白血球を捕捉して回収する方法に関す
る。TECHNICAL FIELD The present invention relates to a filtration membrane for removing blood cells from whole blood, and a method for capturing and recovering red blood cells or white blood cells from whole blood using the filtration membrane.
【0002】[0002]
【従来の技術】血液中の構成成分例えば代謝産物、蛋白
質、脂質、電解質、酵素、抗原、抗体などの種類や濃度
の測定は、通常全血を遠心分離して得られる血清または
血漿を検体として行われている。しかし、遠心分離には
手間と時間を要し、特に少数の検体を急いで処理したい
ときあるいは現場検査などには、電気を動力として遠心
分離機を必要とする遠心分離法は不向きである。そこ
で、濾過により全血から血清あるいは血漿を分離回収す
る方法が検討されてきた。2. Description of the Related Art The types and concentrations of constituents in blood such as metabolites, proteins, lipids, electrolytes, enzymes, antigens and antibodies are usually measured using serum or plasma obtained by centrifugation of whole blood as a sample. Has been done. However, centrifugation requires labor and time, and especially when a small number of specimens are to be processed promptly or in the field, etc., the centrifugal separation method using a centrifuge powered by electricity is unsuitable. Therefore, a method of separating and collecting serum or plasma from whole blood by filtration has been studied.
【0003】濾過によって全血から血清あるいは血漿を
得る方法には、富士写真フイルム(株)製の「プラズマ
フィルターPF」として市販され、特開平2000−8
1432号公報で知られているように、3〜6枚のガラ
ス繊維濾紙をプラスチック製のホルダーに装填して、吸
引により全血を濾過する方法がある。しかし、この濾過
方法では、血漿を150μL程度濾過できるものの全血
を3mL程度必要とし、微量の全血を濾過することがで
きない。A method for obtaining serum or plasma from whole blood by filtration is commercially available as "Plasma Filter PF" manufactured by Fuji Photo Film Co., Ltd.
As known from Japanese Patent No. 1432, there is a method in which 3 to 6 glass fiber filter papers are loaded in a plastic holder and whole blood is filtered by suction. However, this filtration method can filter about 150 μL of plasma, but requires about 3 mL of whole blood, and cannot filter a trace amount of whole blood.
【0004】濾過によって全血から血球を捕捉し、血清
あるいは血漿を得る方法には、特開平10−18591
0号公報に記載された3次元多孔質体を用る方法があ
り、ポリスルホン膜、酢酸セルロース膜などが知られて
いる。しかし、この膜は孔径を均一に作成するのは難し
い。A method for capturing blood cells from whole blood by filtration to obtain serum or plasma is disclosed in JP-A-10-18591.
There is a method of using a three-dimensional porous body described in Japanese Patent Laid-Open No. 0, and polysulfone membrane, cellulose acetate membrane and the like are known. However, it is difficult to make the pore size uniform in this membrane.
【0005】一方、全血から白血球を捕捉して採取し、
これをもとに遺伝子を回収して遺伝子解析あるいは遺伝
子診断に用いることが、近年盛んに行われるようになっ
てきており、全血から白血球を回収する技術が必要とな
ってきている。On the other hand, white blood cells are collected and collected from whole blood,
In recent years, it has been actively used to collect genes based on this and use them for gene analysis or gene diagnosis, and a technique for recovering leukocytes from whole blood is required.
【0006】全血から白血球のみを除去する方法には、
テルモ(株)社製の「イムノガード(登録商標) III−
RC」で実用化されているポリウレタン多孔質フィルタ
ー,日本ポール(株)社で販売している「ポール輸血フィ
ルターPL1J」で実用化されているポリエステルフィ
ルターなどが知られている。しかし、このフィルターは
輸血用の全血から白血球を除去するためのものであり、
微量の全血から白血球を捕捉して白血球を回収すること
が難しい。A method for removing only white blood cells from whole blood is
Terumo Co., Ltd. "Immuno Guard (registered trademark) III-"
There are known a polyurethane porous filter which is practically used in "RC", a polyester filter which is practically used in "POL transfusion filter PL1J" sold by Nippon Pall Ltd., and the like. However, this filter is for removing white blood cells from whole blood for transfusion,
It is difficult to capture leukocytes from a small amount of whole blood and recover leukocytes.
【0007】[0007]
【発明が解決しようとする課題】新生児など微量の全血
しか採血できない場合など、微量の全血から血清あるい
は血漿を急いで得る方法が求められている。また、濾過
によって全血から血球を捕捉する方法において、遺伝子
診断等に用いるために白血球のみを分画して採取する方
法が求められている。There is a need for a method of urgently obtaining serum or plasma from a small amount of whole blood, such as when a small amount of whole blood can be collected from a newborn baby. Further, in the method of capturing blood cells from whole blood by filtration, there is a demand for a method of fractionating and collecting only white blood cells for use in genetic diagnosis and the like.
【0008】[0008]
【課題を解決するための手段】均一な孔径の薄い膜を用
いることで、微量の全血から血球のみを捕捉して血清あ
るいは血漿を回収することができること、および均一な
孔径の大きさによって全血の白血球のみを捕捉して回収
できることを見出した。[Means for Solving the Problems] By using a thin membrane having a uniform pore size, it is possible to collect only blood cells from a small amount of whole blood and recover serum or plasma. It was found that only white blood cells can be captured and collected.
【0009】[0009]
【発明の実施の態様】膜の素材としては、ポリ−ε−カ
プロラクトン、ポリ−3−ヒドロキシブチレート、アガ
ロース、ポリ−2−ヒドロキシエチルアクリレート、ポ
リスルホンなどの非水溶性溶媒に溶解する高分子化合物
を用いることができるが、ポリ−ε−カプロラクトンを
用いることが好ましい。BEST MODE FOR CARRYING OUT THE INVENTION As a material for a membrane, a polymer compound which is soluble in a non-water-soluble solvent such as poly-ε-caprolactone, poly-3-hydroxybutyrate, agarose, poly-2-hydroxyethyl acrylate, and polysulfone. Can be used, but it is preferable to use poly-ε-caprolactone.
【0010】これらの素材だけでもハニカム様の構造の
膜を形成させることができるが、両親媒性の素材を添加
することが好ましい。両親媒性の素材としては、例えば
両親媒性ポリアクリルアミドがある。Although a film having a honeycomb-like structure can be formed with only these materials, it is preferable to add an amphipathic material. Examples of the amphipathic material include amphipathic polyacrylamide.
【0011】膜の素材と両親媒性の素材の混合比率は、
重量比0:1〜1:0の範囲で使用することが好まし
い。より好ましくは、重量比5:1〜20:1の範囲で
ある。The mixing ratio of the membrane material and the amphipathic material is
It is preferable to use the weight ratio in the range of 0: 1 to 1: 0. More preferably, the weight ratio is in the range of 5: 1 to 20: 1.
【0012】キャストする溶媒としては、クロロホル
ム、ジクロロメタン、四塩化炭素、シクロヘキサンなど
膜の素材となる高分子化合物を溶解させることができる
非水溶性の溶媒であればよい。キャストするときのポリ
マー濃度は、高分子膜を形成できる濃度であればよく、
工業的に大量生産をするためには、0.1wt%以上の
できる限り高い濃度で製膜することが望ましい。The solvent for casting may be any water-insoluble solvent such as chloroform, dichloromethane, carbon tetrachloride, cyclohexane, etc., which can dissolve the polymer compound as the material of the membrane. The polymer concentration at the time of casting may be any concentration that can form a polymer film,
For industrial mass production, it is desirable to form a film at a concentration as high as possible, which is 0.1 wt% or more.
【0013】非水溶性の膜の素材、例えばポリ−ε−カ
プロラクトンを、非水溶性の溶媒、例えばクロロホルム
に溶解させているので、高湿度空気によって溶媒を蒸発
させるときに気化熱により空気中の水分が結露し、それ
が溶媒の蒸発とともに徐々に成長して直径0.5〜40
μm程度のサイズの水滴になる。この水滴には非水溶性
のポリ−ε−カプロラクトンは溶解できないから、この
部分が孔(ポア)となった膜が得られる。例えばシャー
レに2次元的にキャストしているので、成長した水滴
は、球の2次元的最密充填構造様に規則正しく配列し、
結果としてハニカム構造の膜が得られる。Since the material of the water-insoluble membrane, for example, poly-ε-caprolactone, is dissolved in the water-insoluble solvent, for example, chloroform, when the solvent is evaporated by the high humidity air, the heat of vaporization causes Condensation of water, which gradually grows as the solvent evaporates and has a diameter of 0.5-40.
Water droplets of about μm size. Since the water-insoluble poly-ε-caprolactone cannot be dissolved in this water droplet, a film having pores in this portion can be obtained. For example, since it is cast two-dimensionally on a petri dish, the grown water droplets are regularly arranged like a two-dimensional close-packed structure of spheres,
As a result, a film having a honeycomb structure is obtained.
【0014】孔径は、キャストする液の濃度及び液量を
調節してシャーレ等の支持層に供給し、雰囲気あるいは
吹き付ける空気の温度、湿度を制御することで、溶媒の
蒸発スピード、結露スピードを制御することによって、
制御することができる。更に、微量の界面活性剤を添加
して水滴の融合を抑えて安定化させることによって、よ
り規則正しいハニカム構造の膜を作成することができ
る。The pore diameter is controlled by controlling the temperature and humidity of the atmosphere or the air to be sprayed by adjusting the concentration and amount of the liquid to be cast and supplying it to a support layer such as a petri dish to control the evaporation speed and dew condensation speed of the solvent. By,
Can be controlled. Furthermore, by adding a trace amount of a surfactant to suppress and stabilize the fusion of water droplets, a more regular honeycomb structure film can be prepared.
【0015】膜に吹き付ける高湿度空気は、相対湿度3
0%および80%のものを主に用いたが、膜の表面に空
気中の水分を結露させることができる湿度であればよ
く、温度によって20〜100%の相対湿度であればよ
いし、空気に限らず窒素、アルゴンなどの比較的不活性
なガスを用いてもよい。The high-humidity air blown onto the membrane has a relative humidity of 3
0% and 80% are mainly used, but the humidity may be such that moisture in the air can be condensed on the surface of the film, and the relative humidity may be 20 to 100% depending on the temperature. Alternatively, a relatively inert gas such as nitrogen or argon may be used.
【0016】膜に吹き付ける高湿度空気の流量は、膜の
表面に空気中の水分を結露させることができ、キャスト
に用いた溶媒を蒸発させることができる流量であればよ
い。The flow rate of the high-humidity air blown onto the film may be any flow rate that allows the moisture in the air to be condensed on the surface of the film and allows the solvent used for casting to be evaporated.
【0017】高湿度空気を吹き付けるときの雰囲気の温
度は、キャストに用いた溶媒が蒸発することができる温
度であればよく、実験室レベルでは15〜32℃、生産
レベルでは5〜80℃の温度であることが望ましい。The temperature of the atmosphere when the high-humidity air is blown may be any temperature at which the solvent used for casting can be evaporated, and is 15 to 32 ° C. at the laboratory level and 5 to 80 ° C. at the production level. Is desirable.
【0018】キャストする溶液の濃度、溶液の量、溶媒
の種類、吹き付ける空気の相対湿度・温度・流量を変え
ることによって、結露、水滴の成長、溶媒の蒸発速度を
制御し、様々な孔径の規則正しいハニカム様の構造の膜
を得ることができ、血液中の成分である、直径約3μm
の血小板、直径約15μmの白血球、変形能が大きいが
直径約7μmの赤血球を、孔径のサイズを変えることに
より各々を分離できるフィルターとして使用できる。By varying the concentration of the solution to be cast, the amount of the solution, the type of solvent, and the relative humidity, temperature, and flow rate of the air to be blown, the dew condensation, the growth of water droplets, and the evaporation rate of the solvent are controlled, and various pore sizes are regular A film with a honeycomb-like structure can be obtained, which is a component in blood and has a diameter of about 3 μm.
Platelets, white blood cells having a diameter of about 15 μm, and red blood cells having a large deformability but having a diameter of about 7 μm can be used as filters that can be separated from each other by changing the pore size.
【0019】また、孔径のほぼ等しい膜を積層すること
によって、フィルターとして分離できる能力を高めるこ
とができる。更に、孔径の異なる複数の膜を積層するこ
とによって、幾つかの生体物質を同時に分離する或いは
分画することができる。例えば、孔径5.5〜8.5μ
mの膜と孔径3.5μm以下の膜を積層して孔径の大き
い膜側から全血を供給することによって、孔径の大きい
膜で白血球を捕捉し、孔径の小さい膜で赤血球を捕捉す
ることが同時に達成できる。Further, by stacking membranes having almost the same pore diameter, the ability to separate as a filter can be enhanced. Furthermore, by stacking a plurality of membranes having different pore sizes, it is possible to simultaneously separate or fractionate some biological substances. For example, pore size 5.5-8.5μ
m membrane and a membrane with a pore diameter of 3.5 μm or less are stacked and whole blood is supplied from the membrane side with a large pore diameter, whereby leukocytes can be captured by a membrane with a large pore diameter and red blood cells can be captured by a membrane with a small pore diameter. Can be achieved at the same time.
【0020】更に、孔径をサブミクロンオーダーに設定
することで、透析などの血液浄化に代表されるような標
的生体物質の選択的分離回収技術としての期待ができ
る。Further, by setting the pore size to the submicron order, it can be expected as a selective separation and recovery technique for a target biological substance represented by blood purification such as dialysis.
【0021】本発明においてハニカム様構造とは、孔径
がほぼ一定の複数の孔が規則正しく配列し、このような
孔が膜を貫通している構造をいう。孔の断面に特に限定
は無く、円形、楕円形、六角形、長方形、正方形等の形
状でよい。In the present invention, the honeycomb-like structure means a structure in which a plurality of pores having a substantially constant pore diameter are regularly arranged and such pores penetrate the membrane. The cross section of the hole is not particularly limited, and may be circular, elliptical, hexagonal, rectangular, square or the like.
【0022】[0022]
【実施例】以下、実施例により本発明をさらに具体的に
説明するが、本発明の範囲は下記の実施例に限定される
ことはない。The present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited to the following examples.
【0023】実施例1 ハニカム様構造の膜の作成
(1)
平均分子量7万〜10万のポリ−ε−カプロラクトン
(化合物1)と両親媒性ポリアクリルアミド(化合物
2)を重量比で10:1の割合で混合したクロロホルム
溶液(ポリマー濃度として0.1〜2wt%)を、直径
10cmのシャーレ上に5mLキャストし、相対湿度3
0〜80%の高湿度空気を毎分1〜20Lの流量で吹き
付け、クロロホルム溶媒を蒸発させることによって、柔
軟性、弾性を有し、力学強度の強いハニカム様構造の膜
を得た。Example 1 Preparation of honeycomb-like structure film (1) Poly-ε-caprolactone (compound 1) having an average molecular weight of 70,000 to 100,000 and amphipathic polyacrylamide (compound 2) in a weight ratio of 10: 1. Chloroform solution (0.1 to 2 wt% as polymer concentration) mixed at a ratio of 5 was cast on a petri dish with a diameter of 10 cm to obtain a relative humidity of 3
By blowing high humidity air of 0 to 80% at a flow rate of 1 to 20 L / min and evaporating the chloroform solvent, a film having a honeycomb-like structure having flexibility, elasticity, and strong mechanical strength was obtained.
【0024】[0024]
【化1】 [Chemical 1]
【0025】[0025]
【化2】 [Chemical 2]
【0026】上記の様々な条件で作成した膜の構造を、
光学顕微鏡、走査型電子顕微鏡で観察したところ、0.
5〜40μmの孔径のハニカム様の構造の膜であり、表
面から裏面へ単一層の孔で貫通している構造であった。
孔径はキャストした全面にわたってきれいな円形をして
おり、サイズもほぼ同一であった。撮影した写真から孔
径を計測し、孔径の分布を求めると変動係数でCV10
%以下であることがわかった。また、レーザーを用いた
光散乱の評価でキャストした膜全面にわたって10次以
上の回折光が観測できたことから、規則性の極めて高い
ポーラスフィルムを作成することができたことがわかっ
た。The structures of the films prepared under the above various conditions are
Observation with an optical microscope and a scanning electron microscope revealed that
The film had a honeycomb-like structure with a pore diameter of 5 to 40 μm, and had a structure in which a single layer of holes penetrated from the front surface to the back surface.
The pore size was a perfect circle over the entire cast surface, and the sizes were almost the same. The hole diameter is measured from the photographed image, and the distribution of the hole diameter is calculated.
It was found to be below%. In addition, since it was possible to observe diffracted light of 10th order or more over the entire surface of the cast film in the evaluation of light scattering using a laser, it was found that a porous film having extremely high regularity could be produced.
【0027】実施例2 ハニカム様構造の膜の作成
(2)
膜となる物質として化合物2からなる両親媒性ポリアク
リルアミドを用い、キャストする溶媒をクロロホルム、
ベンゼン、トルエン、キシレンと変え、溶液濃度を1.
0g/L、キャスト量を30μLとし、キャストさせる
基板にガラスを用い、高湿度空気の流量を0.09L/
分にし、相対湿度を85%にし、温度を20℃にしたと
きに作成できる膜の溶媒依存を評価した。このときの形
態観察結果を図1に示す。図1において、孔径は、上か
ら0.5μm〜10μmである。Example 2 Preparation of honeycomb-like structure film (2) Amphiphilic polyacrylamide consisting of compound 2 was used as a material for the film, and the solvent for casting was chloroform.
Change to benzene, toluene, xylene, and change the solution concentration to 1.
0 g / L, cast amount 30 μL, glass is used for the substrate to be cast, and the flow rate of high humidity air is 0.09 L / L.
Minutes, the relative humidity was set to 85%, and the temperature was set to 20 ° C. The morphological observation result at this time is shown in FIG. In FIG. 1, the pore diameter is 0.5 μm to 10 μm from the top.
【0028】実施例3 ハニカム様構造の膜の作成
(3)
膜となる物質として化合物1からなるポリ−ε−カプロ
ラクトンと化合物2からなる両親媒性ポリアクリルアミ
ドを重量比で10:1の割合で用い、溶媒としてクロロ
ホルムを用い、溶液濃度を10.0g/Lにし、キャス
トする量を5、10、20mLと変え、キャストさせる
基板にガラスを用い、高湿度空気の流量を2.0L/分
にし、相対湿度を30%にし、温度を20℃にしたとき
に作成できる膜のキャスト量依存を評価した。このとき
の形態観察結果を図2に示す。図2において、孔径は、
上から8μm〜35μmである。Example 3 Preparation of Honeycomb-Like Structure Membrane (3) Poly-ε-caprolactone consisting of Compound 1 and amphipathic polyacrylamide consisting of Compound 2 were used as membrane substances at a weight ratio of 10: 1. Chloroform was used as the solvent, the solution concentration was 10.0 g / L, the casting amount was changed to 5, 10, 20 mL, glass was used as the substrate to be cast, and the flow rate of high-humidity air was 2.0 L / min. Then, the cast amount dependence of the film that can be produced when the relative humidity was set to 30% and the temperature was set to 20 ° C. was evaluated. The morphological observation result at this time is shown in FIG. In FIG. 2, the hole diameter is
It is 8 μm to 35 μm from the top.
【0029】実施例4 ハニカム様構造の膜の作成
(4)
膜となる物質として化合物1からなるポリ−ε−カプロ
ラクトンと化合物2からなる両親媒性ポリアクリルアミ
ドを重量比で10:1の割合で用い、溶媒としてクロロ
ホルムを用い、溶液濃度を1、5、10、20g/Lと
変え、キャスト量を10mLとし、キャストさせる基板
にハイドロゲルを用い、高湿度空気の流量を2.0L/
分にし、相対湿度を30%にし、温度を20℃にしたと
きに作成できる膜の溶液濃度依存を評価した。このとき
の形態観察結果を図3に示す。図3において、孔径は、
最小15μm、最大25μmである。Example 4 Preparation of Honeycomb-Like Membrane (4) Poly-ε-caprolactone consisting of Compound 1 and amphipathic polyacrylamide consisting of Compound 2 were used as materials for the membrane in a weight ratio of 10: 1. Chloroform was used as a solvent, the solution concentration was changed to 1, 5, 10, and 20 g / L, the casting amount was 10 mL, hydrogel was used as the substrate to be cast, and the flow rate of high-humidity air was 2.0 L / L.
Minutes, the relative humidity was set to 30%, and the temperature was set to 20 ° C. to evaluate the solution concentration dependence of the film that can be formed. The morphological observation result at this time is shown in FIG. In FIG. 3, the hole diameter is
The minimum is 15 μm and the maximum is 25 μm.
【0030】実施例5 ハニカム様構造の膜の作成
(5)
膜となる物質として化合物1からなるポリ−ε−カプロ
ラクトンを用い、溶媒としてクロロホルムを用い、溶液
濃度を1.0g/Lとし、キャスト量を5mLとし、キ
ャストさせる基板をアガロースゲル、ガラス、マイカ、
PHEMAと変え、高湿度空気の流量を2.0L/分に
し、相対湿度を30%にし、温度を20℃にしたときに
作成できる膜のキャスト基板依存を評価した。このとき
の形態観察結果を図4に示す。図4において、孔径は、
最小7μm、最大14μmである。Example 5 Preparation of Honeycomb-Like Structure Membrane (5) Poly-ε-caprolactone consisting of Compound 1 was used as the substance forming the membrane, chloroform was used as the solvent, the solution concentration was 1.0 g / L, and casting was performed. Set the volume to 5 mL and cast the substrate on agarose gel, glass, mica,
Instead of PHEMA, the flow rate of high-humidity air was set to 2.0 L / min, the relative humidity was set to 30%, and the temperature was set to 20 ° C. The morphological observation result at this time is shown in FIG. In FIG. 4, the hole diameter is
The minimum is 7 μm and the maximum is 14 μm.
【0031】なお、図1〜図4において、バーの長さは
すべて20μmである。In FIGS. 1 to 4, the length of each bar is 20 μm.
【0032】実施例6 濾過性能の評価(1)
作成したハニカム様の構造の膜の血液濾過性能を評価す
るに先立ち、粒径が既知のポリスチレン粒子の通過実験
を行い、孔径を変えることによって通過する粒子の種類
と通過率を調べた。結果を表1に示す。孔径5.5〜
8.5μmの膜を用いると、直径3μmの粒子は通過す
るが直径10μm以上の粒子は全く通過しないことを初
めて明らかにすることができた。Example 6 Evaluation of Filtration Performance (1) Prior to evaluating the blood filtration performance of the formed honeycomb-like structure membrane, polystyrene particles having a known particle diameter were subjected to a passage experiment and passed through by changing the pore diameter. The type of particles and the passage rate were investigated. The results are shown in Table 1. Pore size 5.5
It was possible for the first time to show that with the 8.5 μm membrane, particles with a diameter of 3 μm pass but particles with a diameter of 10 μm and above do not pass at all.
【0033】[0033]
【表1】 粒子通過率は、パーティクルカウンターで計測。[Table 1] The particle passage rate is measured with a particle counter.
【0034】実施例7 濾過性能の評価(2)
作成したハニカム様の構造の膜を用いて、ヒト全血中の
白血球の捕捉実験を行った。孔径5.2μm、9.8μ
mの膜を用い、ヘパリン採血管で採血した人全血を濾過
させ、血球計算板に血液をキャストして白血球の数を計
測したところ、濾過前では4800個/μLあった白血
球数が、濾過後は0個/μLになっていることがわかっ
た(表2)。また、濾過した濾液を3000回転で10
分遠心分離して得られた上清の色を目視で確認したとこ
ろ、溶血は確認されなかった。Example 7 Evaluation of Filtration Performance (2) A leukocyte trapping experiment in human whole blood was carried out by using the prepared membrane having a honeycomb-like structure. Pore size 5.2μm, 9.8μ
Using a membrane of m, human whole blood collected with a heparin blood collection tube was filtered, and blood was cast on a hemocytometer to measure the number of white blood cells. The number of white blood cells was 4800 cells / μL before filtration. After that, it was found that the number was 0 / μL (Table 2). Also, the filtered filtrate is rotated at 3000 rpm for 10 times.
When the color of the supernatant obtained by centrifugal separation was visually confirmed, no hemolysis was confirmed.
【0035】[0035]
【表2】 濾過前の白血球数4800個/μL[Table 2] White blood cell count before filtration 4800 / μL
【0036】実施例8 濾過性能の評価(3)
作成したハニカム様の構造の膜を用いて、ヒト全血中の
赤血球の捕捉実験を行った。孔径3.5〜5.5μmの
膜を用い、各々直径5mmに3枚打ち抜いて積層してニ
トロセルロース膜の上に静置した。ヘパリン採血管で採
血したヘマトクリット値40%のヒト全血を、同一全血
を遠心分離して得られた血漿で希釈してヘマトクリット
値2.5%に調製した全血にしたものを、積層した膜の
上に5μL点着して10秒間放置し、その後に積層した
膜を持ち上げ、濾過されてニトロセルロース膜に転写し
た血漿に赤血球の赤い色が残存しているかどうかの評価
を行ったところ、孔径が3.5μmの膜で赤い色が見と
められず、赤血球を捕捉できていることが確認できた
(表3)。Example 8 Evaluation of Filtration Performance (3) An erythrocyte trapping experiment in human whole blood was carried out using the prepared membrane having a honeycomb-like structure. Using a membrane having a pore size of 3.5 to 5.5 μm, three pieces each having a diameter of 5 mm were punched out, laminated, and allowed to stand on a nitrocellulose membrane. Human whole blood having a hematocrit value of 40% collected by a heparin blood collection tube was diluted with plasma obtained by centrifuging the same whole blood to obtain whole blood prepared to have a hematocrit value of 2.5%, and the whole blood was laminated. When 5 μL was spotted on the membrane and left for 10 seconds, then the laminated membrane was lifted up, and it was evaluated whether or not the red color of red blood cells remained in the plasma transferred to the nitrocellulose membrane by filtration. No red color was observed in the membrane having a pore size of 3.5 μm, confirming that red blood cells could be captured (Table 3).
【0037】[0037]
【表3】 [Table 3]
【0038】[0038]
【発明の効果】本発明により、微量の全血から、血清あ
るいは血漿と血球を分離し、さらには白血球のみを捕捉
して分離することができる。Industrial Applicability According to the present invention, blood cells can be separated from serum or plasma from a trace amount of whole blood, and further only white blood cells can be captured and separated.
【図1】 ハニカム様の膜を作成するときの孔径の溶媒
依存を示したものである。FIG. 1 shows the solvent dependence of the pore size when forming a honeycomb-like film.
【図2】 ハニカム様の膜を作成するときの孔径のキャ
スト量依存を示したものである。[Fig. 2] Fig. 2 shows the cast amount dependency of the pore size when a honeycomb-like film is formed.
【図3】 ハニカム様の膜を作成するときの孔径の濃度
依存を示したものである。[Fig. 3] Fig. 3 shows the concentration dependence of the pore diameter when forming a honeycomb-like film.
【図4】ハニカム様の膜を作成するときの孔径のキャス
トする基板依存を示したものである。[Fig. 4] Fig. 4 shows dependence of a pore size on a substrate to be cast when a honeycomb-like film is formed.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) B01D 69/12 B01D 69/12 71/48 71/48 G01N 33/48 G01N 33/48 H (72)発明者 境野 佳樹 埼玉県朝霞市泉水三丁目11番46号 富士写 真フイルム株式会社内 (72)発明者 伊藤 敏古 埼玉県朝霞市泉水三丁目11番46号 富士写 真フイルム株式会社内 (72)発明者 寺島 薫 埼玉県朝霞市泉水三丁目11番46号 富士写 真フイルム株式会社内 Fターム(参考) 2G045 CA25 HA06 HA14 JA07 2G052 AA30 AD26 CA40 EA03 EA11 JA16 4C077 AA12 BB02 EE01 KK11 LL02 LL13 NN02 PP13 PP15 4D006 GA02 GA13 MA04 MA08 MA22 MB06 MC48X MC54X NA10 NA34 NA41 PB44 PB45 PC41 PC80 ─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 7 Identification code FI theme code (reference) B01D 69/12 B01D 69/12 71/48 71/48 G01N 33/48 G01N 33/48 H (72) Invention Person Sakano Yoshiki 3-11-46, Izumisui, Asaka-shi, Saitama, Fuji Shashin Film Co., Ltd. (72) Inventor Toshiko Ito 3--11, Sensui, Asaka-shi, Saitama Prefecture, Fujifilm Shin-Film Co., Ltd. (72) Inventor Kaoru Terashima 3-11-46 Izumisui, Asaka-shi, Saitama Prefecture F-term in Fuji Shashin Film Co., Ltd. (reference) 2G045 CA25 HA06 HA14 JA07 2G052 AA30 AD26 CA40 EA03 EA11 JA16 4C077 AA12 BB02 EE01 KK15 4N006 PP13 LL02 LL02 LL02 LL02 LL006 GA02 GA13 MA04 MA08 MA22 MB06 MC48X MC54X NA10 NA34 NA41 PB44 PB45 PC41 PC80
Claims (4)
ツキが変動係数20%以下の膜からなる血液濾過膜1. A blood filtration membrane having a pore size of 0.5 to 40 μm and a variation in the pore size of 20% or less in variation coefficient.
の血液濾過膜2. The blood filtration membrane according to claim 1, which has a honeycomb-like structure.
質からなる請求項1または請求項2に記載の血液濾過膜3. The blood filtration membrane according to claim 1, which is composed of a substance mainly containing poly-ε-caprolactone.
の、同一の平均孔径の膜あるいは異なる平均孔径の膜を
2枚以上用いることによる血液濾過方法4. A method for hemofiltration by using two or more membranes having the same average pore diameter or different membranes having different average pore diameters according to any one of claims 1 to 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001342484A JP2003149096A (en) | 2001-11-07 | 2001-11-07 | Blood filter film and method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001342484A JP2003149096A (en) | 2001-11-07 | 2001-11-07 | Blood filter film and method therefor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006109576A Division JP2006194908A (en) | 2006-04-12 | 2006-04-12 | Method for manufacturing blood filtration film, and filtration method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2003149096A true JP2003149096A (en) | 2003-05-21 |
Family
ID=19156333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001342484A Pending JP2003149096A (en) | 2001-11-07 | 2001-11-07 | Blood filter film and method therefor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2003149096A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005051450A1 (en) | 2003-11-28 | 2005-06-09 | Zeon Medical, Inc. | Cell growth-inhibiting film, medical instrument and stent for digestive organs |
| WO2006022358A1 (en) * | 2004-08-24 | 2006-03-02 | Teijin Limited | Laminated body |
| JP2007002241A (en) * | 2005-05-27 | 2007-01-11 | Fujifilm Holdings Corp | Method for manufacturing self-assembled structure |
| JPWO2005014149A1 (en) * | 2003-08-07 | 2007-09-27 | 旭化成株式会社 | Composite porous membrane and method for producing the same |
| WO2009038061A1 (en) | 2007-09-21 | 2009-03-26 | Fujifilm Corporation | Multilayered film and process for producing the same |
| WO2009038060A1 (en) * | 2007-09-21 | 2009-03-26 | Fujifilm Corporation | Multilayer film and process for producing the same |
| JP2009207430A (en) * | 2008-03-05 | 2009-09-17 | Asahi Kasei Corp | Composite membrane and method for producing the same |
| JP2010201549A (en) * | 2009-03-03 | 2010-09-16 | Fuji Xerox Co Ltd | Microchannel device, separation method, and separator |
| JP2013524255A (en) * | 2010-04-15 | 2013-06-17 | サイトゲン カンパニー リミテッド | Microfluidic device |
| JP2016195986A (en) * | 2015-04-06 | 2016-11-24 | 富士フイルム株式会社 | Filter medium, filter unit, and cell sheet |
| WO2018177607A1 (en) * | 2017-03-29 | 2018-10-04 | Condalign As | A method for forming a body comprising at least one through-going passage |
| WO2019230257A1 (en) * | 2018-05-31 | 2019-12-05 | 日東電工株式会社 | Blood filtration membrane |
-
2001
- 2001-11-07 JP JP2001342484A patent/JP2003149096A/en active Pending
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012006010A (en) * | 2003-08-07 | 2012-01-12 | Asahi Kasei Kuraray Medical Co Ltd | Composite porous membrane and process for producing the same |
| JPWO2005014149A1 (en) * | 2003-08-07 | 2007-09-27 | 旭化成株式会社 | Composite porous membrane and method for producing the same |
| US8999167B2 (en) | 2003-08-07 | 2015-04-07 | Asahi Kasei Medical Co., Ltd. | Composite porous membrane and process for producing the same |
| EP1666129A4 (en) * | 2003-08-07 | 2009-07-15 | Asahi Chemical Ind | Composite porous membrane and process for producing the same |
| JP4863714B2 (en) * | 2003-08-07 | 2012-01-25 | 旭化成クラレメディカル株式会社 | Composite porous membrane and method for producing the same |
| WO2005051450A1 (en) | 2003-11-28 | 2005-06-09 | Zeon Medical, Inc. | Cell growth-inhibiting film, medical instrument and stent for digestive organs |
| WO2006022358A1 (en) * | 2004-08-24 | 2006-03-02 | Teijin Limited | Laminated body |
| JP2007002241A (en) * | 2005-05-27 | 2007-01-11 | Fujifilm Holdings Corp | Method for manufacturing self-assembled structure |
| WO2009038061A1 (en) | 2007-09-21 | 2009-03-26 | Fujifilm Corporation | Multilayered film and process for producing the same |
| WO2009038060A1 (en) * | 2007-09-21 | 2009-03-26 | Fujifilm Corporation | Multilayer film and process for producing the same |
| JP2009207430A (en) * | 2008-03-05 | 2009-09-17 | Asahi Kasei Corp | Composite membrane and method for producing the same |
| JP2010201549A (en) * | 2009-03-03 | 2010-09-16 | Fuji Xerox Co Ltd | Microchannel device, separation method, and separator |
| JP2013524255A (en) * | 2010-04-15 | 2013-06-17 | サイトゲン カンパニー リミテッド | Microfluidic device |
| JP2016195986A (en) * | 2015-04-06 | 2016-11-24 | 富士フイルム株式会社 | Filter medium, filter unit, and cell sheet |
| WO2018177607A1 (en) * | 2017-03-29 | 2018-10-04 | Condalign As | A method for forming a body comprising at least one through-going passage |
| US11986776B2 (en) | 2017-03-29 | 2024-05-21 | Condalign As | Method for forming a body comprising at least one through-going passage |
| WO2019230257A1 (en) * | 2018-05-31 | 2019-12-05 | 日東電工株式会社 | Blood filtration membrane |
| JP2019209238A (en) * | 2018-05-31 | 2019-12-12 | 日東電工株式会社 | Hemofiltration membrane |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1666129B1 (en) | Composite porous membrane | |
| JP4252449B2 (en) | Leukocyte removal filter material coating polymer and filter material | |
| Yu et al. | High performance thin-film nanofibrous composite hemodialysis membranes with efficient middle-molecule uremic toxin removal | |
| JP2003149096A (en) | Blood filter film and method therefor | |
| TWI517898B (en) | Membrane suitable for blood filtration | |
| US6849185B1 (en) | Charged membrane | |
| EP0502213A1 (en) | Leukocyte removal method and leukocyte removal filter system | |
| JP5879631B2 (en) | High throughput membrane with rough surface | |
| KR20180021238A (en) | Nanofiber containing composite structures | |
| JP4271265B2 (en) | Leukocyte removal filter material | |
| WO2000069549A1 (en) | Charged membrane | |
| KR20170113638A (en) | A method for purifying a biological material of interest in a sample using nanofiber ultrafiltration membranes operating in tangential flow filtration mode | |
| WO2001066171A1 (en) | Novel leukapheretic filter | |
| JP2002526172A (en) | Biological fluid filters and systems | |
| JP2006194908A (en) | Method for manufacturing blood filtration film, and filtration method | |
| JPH0725776A (en) | Filter material for selectively removing leukocyte | |
| CN116943442B (en) | Preparation method of ultrafiltration membrane with controllable thickness of humidity sensing small pore layer and ultrafiltration equipment | |
| CN112384259B (en) | Blood processing filter and method for manufacturing the same | |
| Jin et al. | Efficient leukocyte removal and enhanced biocompatibility using PVDF membranes prepared by vapor-induced phase separation | |
| JP4892824B2 (en) | Method for producing hollow fiber membrane separation membrane and method for using hollow fiber membrane separation membrane produced by the production method | |
| Dizon et al. | Assessment of the blood separation performances of asymmetric cellulose acetate membranes prepared through combined vapor-induced phase separation and electrospinning | |
| JP4148309B2 (en) | Fine aggregate removal filter material | |
| Fu et al. | Thermo-responsive bioseparation engineered for human leukocyte enrichment process driven by functionalized polypropylene bio-separators | |
| JPH03146067A (en) | Blood plasma filtering method | |
| US20240207765A1 (en) | Viral filtration media, articles, and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040622 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20051006 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051012 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051207 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20051207 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060216 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060720 |